Your session is about to expire
← Back to Search
JANX008 for Advanced Cancer
Study Summary
This trial is testing the safety and effectiveness of a new drug for advanced cancer expressing EGFR.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I use supplemental oxygen.My cancer did not respond or I couldn't tolerate all treatments known to help my type of tumor.I have previously received EGFR-targeted immune therapy.I am 18 years old or older.I have been treated with CD3 bispecific antibodies before.My cancer is confirmed to be advanced or has spread, including lung, head and neck, colon, or kidney cancer.I do not have any serious infections.I don't have any health issues that could affect the study's safety or results.My organs are working well.You must have at least one specific type of visible abnormality that can be measured according to a particular set of rules.I have a serious heart condition.I haven't had cancer treatment in the last 28 days or within 5 half-lives of the drug.
- Group 1: Dose Escalation
- Group 2: Backfill Expansion
- Group 3: Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What criteria must potential trial participants satisfy?
"This clinical trial is enrolling up to 130 qualified patients, aged 18-100, who have a diagnosis of kidney cancer."
Has the FDA sanctioned Dose Escalation for clinical use?
"Taking into account the limited clinical data associated with Dose Escalation, our team gave it an overall safety rating of 1."
Are there any open vacancies for this examination?
"Affirmative. Clinicaltrials.gov records reveal that this research is actively in search of trial participants, with the original posting taking place on March 1st 2023 and most recent editing occurring 29 days later."
What is the scope of participation in this clinical trial?
"Affirmative, clinicaltrials.gov indicates that this study is currently looking for participants. It was made available on March 1st 2023 and the most recent update was issued on March 29th 2023. 130 patients are expected to join from one location."
Are individuals of mature age eligible for this clinical trial?
"To qualify for this clinical study, participants must be between 18 and 100 years of age. Separately, there are 125 trials which encompass minors, as well as 4147 studies available to seniors."
Share this study with friends
Copy Link
Messenger